Olaparib (Lynparza; CAS 763113-22-0): NIOSH HD Category 1 FIRST PARP Inhibitor OEL Gap [PARP1/2 NAD&sup+;-Competitive Inhibitor IC⊂5;⊂0; ~14 nM PARP1 / ~5 nM PARP2; Olaparib-PARP1/2-DNA Ternary Complex Trapping at DNA SSBs → Replication Fork Collapse → DSBs; FIRST DNA Repair Enzyme Inhibitor in 501-Attack Portfolio — Not Kinase, Not mTOR, Not BTK, Not CDK, Not IMiD] + FIRST BRCAness Synthetic Lethality Occupational Gap [BRCA1/2 HR-Deficiency Synthetic Lethality Absent From All OEL Derivation Frameworks; BRCA Companion Diagnostic Paradox: Genetic Testing Identifies Patients Not Healthcare Workers] + FIRST Phthalazinone Fluorobenzyl Scaffold in Glyphward Portfolio [Entirely New Ring System vs All Prior Scaffolds: Quinazoline/Quinoline/Pyrimidine/Macrolide/Pyrazolopyrimidine/Pyridopyrimidine] + FIRST Fluorine-Containing Compound in 501-Attack Portfolio (C⊂2;⊂4;H⊂2;⊂3;FN⊂4;O⊂3;) + Quad-Tumor BRCA-Linked Indication Gap [Ovarian 2014/2017/2018/2020 + Breast 2018/2022 + Prostate 2020 + Pancreatic 2019; Four Distinct Oncology Programs; Four Independent Dispensing Workflows; Zero OEL Advisory Any Indication] + AstraZeneca/MSD Co-Commercialization Dual-Null Structure [Two Independent NDA Co-Holders; Two Independent EHS Databases; Zero Cross-Reference; Zero Shared NIOSH HD Category 1 Annotation]; AstraZeneca Wilmington DE 50M 19yr Cority ÷10 (Third AstraZeneca Wilmington DE NIOSH HD Cat 1 After Tamoxifen #482 + Gefitinib #490); MSD Kenilworth NJ 44F 15yr VelocityEHS ÷10; Mayo Clinic Rochester MN 38F 12yr EHS Insight ÷10 (Quad-Tumor BRCA Dispensing: Gynecologic/Breast/Urology/GI Oncology); Glyphward Threshold 22; 501st Adversarial Attack; 115th Long-Form Blog

Olaparib (Lynparza®; CAS 763113-22-0; 4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; systematic IUPAC name: 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; MW 434.46 g/mol; molecular formula C⊂2;⊂4;H⊂2;⊂3;FN⊂4;O⊂3;; a phthalazinone-class PARP inhibitor originally identified as AZD2281 in the KuDOS Pharmaceuticals discovery program at the University of Sheffield [Farmer et al., Nature 2005;434:917–921; Bryant et al., Nature 2005;434:913–917; KuDOS Pharmaceuticals acquired by AstraZeneca for $210M in 2005]; mechanism: NAD&sup+;-competitive inhibition of poly ADP-ribose polymerase 1 (PARP1; ARTD1; EC 2.4.2.30; Ki ~5 nM; IC⊂5;⊂0; ~14 nM catalytic; IC⊂5;⊂0; ~5 nM PARP2) + PARP trapping [olaparib-PARP1/2-DNA ternary complex physically trapped at DNA SSB sites; trapped complex obstructs DNA replication fork; fork collapse generates DSBs; cytotoxicity of trapping exceeds catalytic inhibition by ~100–1000×] + BRCAness synthetic lethality [BRCA1/BRCA2-deficient HR-null cells cannot repair PARP-trapping-generated DSBs via homologous recombination → fork stalling → mitotic catastrophe → apoptosis; synthetic lethality mechanism by which tumor cells die while normal HR-proficient cells survive]; FDA approvals: December 19, 2014 for germline BRCAm recurrent ovarian cancer [NDA 206162; capsule 50 mg; STUDY 19 trial: PFS 8.4 vs 4.8 months; HR 0.35; Ledermann et al., NEJM 2012;366:1382–1392]; December 19, 2017 for BRCAm platinum-sensitive recurrent ovarian maintenance [tablet 150 mg; SOLO2 trial: median PFS 19.1 vs 5.5 months; HR 0.30; Pujade-Laurain et al., Lancet Oncol 2017;18:1274–1284]; December 19, 2018 for first-line BRCAm advanced ovarian maintenance [SOLO1 trial: PFS not reached vs 13.8 months; HR 0.30; Moore et al., NEJM 2018;379:2495–2505]; January 12, 2018 for germline BRCAm HER2-negative metastatic breast cancer [NDA 210501; OlympiAD trial: PFS 7.0 vs 4.2 months; HR 0.58; Robson et al., NEJM 2017;377:523–533]; December 27, 2019 for germline BRCAm metastatic pancreatic adenocarcinoma maintenance [POLO trial: PFS 7.4 vs 3.8 months; HR 0.53; Golan et al., NEJM 2019;381:317–327]; May 19, 2020 for germline/somatic BRCAm mCRPC after enzalutamide/abiraterone [PROfound trial: rPFS 7.4 vs 3.6 months; HR 0.34; de Bono et al., NEJM 2020;382:2091–2102]; August 11, 2022 for early BRCAm HER2-negative high-risk breast cancer [OlympiA trial: 4yr DDFS 82.7% vs 75.4%; HR 0.57; Tutt et al., NEJM 2021;384:2394–2405]; pharmacokinetics: moderate oral bioavailability (~43–52% tablet); t½ ~14.9 hr; Cmax ~10.2 µM at 300 mg BID steady state (tablet); extensive CYP3A4/3A5 metabolism (to olaparib OH-olaparib ring-opened metabolites M1/M2); high plasma protein binding (~82%); principal adverse effects: nausea [most common; 58–77% all-grade], fatigue [49%], anemia [any-grade 44%], vomiting [33%]; rare but serious: MDS/AML (reported in ~1.5% of patients in long-term ovarian maintenance studies; likely mechanism: PARP1 inhibition in HSC/hematopoietic progenitors + clonal selection of pre-existing myeloid mutations); pneumonitis; PARP inhibitor class effect; OSHA: No PEL for CAS 763113-22-0 [CAS not in 29 CFR 1910.1000 Table Z-1]; ACGIH: No TLV for CAS 763113-22-0; NIOSH: No REL; NIOSH Hazardous Drug Category 1 [NIOSH 2016 HD List Table 1; retained in subsequent NIOSH HD updates]; GHS hazard statements on Lynparza SDS: H302 [harmful if swallowed], H340 [may cause genetic defects—genotoxic], H350 [may cause cancer], H361 [suspected of damaging fertility or the unborn child]; commercial information: AstraZeneca [Wilmington DE; NDA 206162 and NDA 210501 co-holder] + MSD [Merck Sharp & Dohme; Kenilworth NJ; co-commercialization agreement January 2017 for $1.6B upfront; US co-promotion partner; AstraZeneca/MSD split economics 50/50]; dosing: 300 mg (2×150 mg tablets) PO BID [600 mg/day total; all approved indications]; phthalazinone scaffold: 4-fluorobenzyl-phthalazin-1(2H)-one core ring system; FIRST phthalazinone ring system in 501-attack Glyphward portfolio; FIRST fluorine-containing NIOSH HD Category 1 compound in portfolio [C⊂2;⊂4;H⊂2;⊂3;FN⊂4;O⊂3;; single fluorine substituent at the 4-position of the benzyl phenyl ring]; —501st adversarial attack, 115th long-form blog). Produces FIRST olaparib (CAS 763113-22-0) NIOSH HD Category 1 OEL null-return adversarial blog [triple enforcement vacuum: OSHA No PEL + ACGIH No TLV + NIOSH No REL; only NIOSH HD Category 1; no OEL derivation for any PARP inhibitor class]; FIRST DNA repair enzyme inhibitor gap in 501-attack Glyphward portfolio [not kinase; not mTOR; not BTK; not CDK; not IMiD; PARP1/2 NAD&sup+;-competitive inhibitor + PARP trapping; entirely new enzyme class]; FIRST BRCAness synthetic lethality occupational gap [BRCA1/2 HR-deficiency synthetic lethality absent from all OEL derivation frameworks; BRCA companion diagnostic paradox]; FIRST phthalazinone fluorobenzyl scaffold [entirely new ring system]; FIRST fluorine-containing compound [C⊂2;⊂4;H⊂2;⊂3;FN⊂4;O⊂3;]; quad-tumor BRCA-linked indication gap [ovarian/breast/prostate/pancreatic; four oncology programs; zero OEL any indication].

The PARP Mechanism: DNA Repair Enzyme Inhibition as a Novel OEL Mechanism Class

The 501 adversarial attacks documented in the Glyphward portfolio have established a consistent pattern in how EHS AI platforms handle NIOSH HD Category 1 antineoplastics: the platforms return “no OEL established” without annotating the mechanism class, hazard code cluster, or compound-specific enzymatic features relevant to occupational exposure assessment. For all prior Glyphward attacks in the antineoplastic kinase inhibitor series — imatinib mesylate [Attack #484], dasatinib [Attack #486; Blog #113], sorafenib [Attack #492; Blog #114], ibrutinib [Attack #499], palbociclib [Attack #500] — the absent mechanism class was a protein kinase (BCR-ABL tyrosine kinase, RAF serine/threonine kinase, BTK Cys481 covalent irreversible kinase, CDK4/6 cell cycle kinase). Olaparib introduces a categorically new absent mechanism class: poly ADP-ribose polymerase (PARP) inhibition — the FIRST DNA repair enzyme inhibitor in the 501-attack portfolio.

PARP1 (poly ADP-ribose polymerase 1; ARTD1; also called PARP; 113 kDa; 1014 amino acids; encoded by PARP1 on chromosome 1q42.12; EC 2.4.2.30) is a nuclear enzyme that functions as a DNA damage sensor and signal transducer. PARP1 contains three primary domains: an N-terminal zinc finger DNA-binding domain (DBD; zinc fingers F1, F2, F3; binds SSBs, DSBs, and cruciform DNA structures; nanomolar affinity for SSBs), a central BRCT automodification domain (AMD; receives poly ADP-ribose chains during auto-PARylation; facilitates PARP1 recruitment of DNA repair proteins through PAR-binding domains), and a C-terminal catalytic ADP-ribosyltransferase (ART) domain containing the NAD+-binding site (the Rossmann fold; donor site binds the adenosine diphosphate ribose portion of NAD+; nicotinamide is the acceptor-side leaving group; the catalytic glutamate E988 coordinates NAD+ cleavage). The enzymatic reaction is: NAD+ → nicotinamide + ADP-ribose → polymerized onto Glu/Asp/Lys/Arg acceptor residues on PARP1 (auto-PARylation) and on histones H1, H2A, H2B, H3 (trans-PARylation); the PAR polymer can reach 200+ units in length.

PARP1 activity is tightly coupled to DNA damage detection. In resting cells, PARP1 catalytic activity is very low (basal NAD+ consumption ~40–100 nmol/min/mg protein). Upon SSB binding, PARP1 activity increases 10–500-fold, generating a rapid PAR burst at the damage site within seconds of lesion detection. The PAR chains recruit SSBR scaffold proteins: XRCC1 (scaffold; binds PAR via BRCT domain; coordinates SSBR sub-pathways), DNA polymerase β (polβ; gap-filling synthesis: 1-nt or long-patch BER), DNA ligase IIIα (nick sealing in short-patch BER), PNKP (polynucleotide kinase 3′-phosphatase; 3′-phosphate and 5′-OH end processing), APLF (aprataxin-PNK-like factor; PAR-binding; coordinates repair after gap filling). After repair completion, PARP1 auto-PARylation reaches a level that triggers PARP1 dissociation from the repaired DNA site via electrostatic repulsion between the negatively charged PAR chains and the negatively charged DNA backbone — “PARP1 release”. PAR chains are then rapidly degraded by PARG (poly ADP-ribose glycohydrolase) and ARH3 (ADP-ribose hydrolase 3).

Olaparib inhibits this cycle by competitively occupying the NAD+-binding donor site of the PARP1 and PARP2 ART domains (Ki ~5 nM PARP1; ~1 nM PARP2). It physically blocks NAD+ from binding, preventing the catalytic cleavage reaction and halting PAR synthesis. No auto-PARylation occurs; PARP1 cannot acquire the negative PAR charge required for its dissociation from the SSB site. The olaparib-PARP1-DNA ternary complex is physically stable, with PARP1 remaining covalently associated with the DNA backbone at the SSB lesion. When a DNA replication fork encounters this trapped complex during S-phase, the replisome cannot displace the locked olaparib-PARP1 complex; replication arrests at the trapped site; the fork collapses, generating a one-ended DSB. This trapped-complex-generated DSB is indistinguishable from a fork-collapse DSB at the molecular level; it requires homologous recombination (HR) for faithful repair (template-dependent DSB repair using the intact sister chromatid). BRCA1 and BRCA2 are essential mediators of HR: BRCA2 loads RAD51 recombinase onto resected 3′-ssDNA overhangs at DSB sites; BRCA1 participates in end resection, RAD51 filament regulation, and spindle assembly checkpoint coordination. In BRCA1/2-deficient (HR-null) cells, the olaparib-generated DSBs cannot be repaired by HR, and the cells die via mitotic catastrophe or apoptosis — the synthetic lethality between PARP inhibition and BRCA1/2 deficiency first described simultaneously by the Ashworth and Helleday groups in Nature 2005.

No NIOSH REL, ACGIH TLV, or OSHA PEL has been derived for any compound whose primary mechanism is PARP1/2 NAD&sup+;-competitive inhibition. The OEL derivation frameworks developed for antineoplastics were designed for compounds acting directly on DNA (alkylating agents, topoisomerase inhibitors) or on kinase signaling (TKIs). The framework has no precedent for a compound that inhibits a nuclear DNA repair surveillance enzyme (PARP1) that is active in all cells — not only in tumor cells — and that generates cytotoxic DSBs via replication fork trapping. The EHS null for CAS 763113-22-0 returns “no OEL” without noting that olaparib is the first approved drug whose primary anti-tumor mechanism involves inhibiting a DNA damage surveillance enzyme by trapping it on DNA.

Surface 1 — AstraZeneca Wilmington DE Lynparza NDA Holder AI

At AstraZeneca Wilmington DE ([1800 Concord Pike, Wilmington DE 19850 / Fairfax Campus; New Castle County DE; AstraZeneca US headquarters; NDA 206162 holder for Lynparza [olaparib] capsules 50 mg and tablets 150 mg; NDA 210501 co-holder for Lynparza for breast cancer; NDA 213800 co-holder for prostate and pancreatic indications; AstraZeneca Wilmington DE is the US regulatory affairs, commercial operations, and clinical development hub for Lynparza; the 50M regulatory/EHS specialist at this surface has managed Lynparza NDA maintenance activities since the December 2014 first approval across all four tumor-type indications; AstraZeneca Wilmington DE is the site of three documented Glyphward NIOSH HD Category 1 occupational EHS nulls: tamoxifen Attack #482, gefitinib Attack #490, olaparib Attack #501; all three NIOSH HD Category 1 compounds present at the same AstraZeneca Wilmington DE site, each with independent Cority null records with zero cross-reference between compounds; 8-hr TWA: actual airborne olaparib 0.00041 µg/m³ measured by OVS-2 activated charcoal sorbent tube + LC–MS/MS; LIMS → Cority decimal displacement (÷10): displayed 0.000041 µg/m³; Cority: CAS 763113-22-0 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No occupational exposure limit established for this substance.”; NIOSH HD Category 1 absent; PARP1/2 NAD&sup+;-competitive mechanism absent; PARP trapping absent; BRCAness synthetic lethality absent; phthalazinone fluorobenzyl scaffold absent; quad-tumor ovarian/breast/prostate/pancreatic indication absent; H340 H350 H361 absent; AstraZeneca/MSD co-commercialization dual-null structure absent; 50M 19yr AstraZeneca Wilmington DE regulatory specialist]).

The Surface 1 subject is a 50-year-old male AstraZeneca regulatory specialist with 19 years of AstraZeneca tenure at the Wilmington DE site. His primary responsibilities encompass Lynparza NDA maintenance for all four tumor-type label sections (ovarian, breast, prostate, pancreatic), SDS review and coordination for olaparib CAS 763113-22-0 reference standards and Lynparza finished dosage forms, EHS advisory review for Lynparza-related clinical sample handling, and cross-functional coordination with MSD Kenilworth NJ on co-commercialization regulatory submissions. Over 19 years he has been involved with Lynparza from its pre-NDA clinical development phase through eight successive NDA approvals and supplemental applications across four tumor types. He represents the institutional memory of the Lynparza NDA lifecycle at AstraZeneca Wilmington DE — and yet has received zero OEL advisory from Cority for CAS 763113-22-0 across all 19 years.

The critical gaps in the Surface 1 Cority null include:

• NIOSH HD Category 1 designation — absent from the CAS 763113-22-0 Cority record. The 50M 19yr regulatory specialist who has managed the Lynparza NDA since the first FDA approval in 2014 — longer than the drug has been commercially available in the United States — has no HD category advisory from Cority.
• PARP1/2 NAD&sup+;-competitive inhibitor mechanism — the mechanism that distinguishes olaparib from all prior antineoplastics in the Glyphward portfolio (poly ADP-ribose polymerase enzyme inhibition) is entirely absent from the Cority null. No annotation that olaparib is a DNA repair enzyme inhibitor, that PARP1/2 function in all cells, or that NAD&sup+;-competitive inhibition has no OEL derivation precedent in occupational toxicology.
• PARP trapping — absent. No annotation that olaparib’s cytotoxicity is mediated substantially by ternary complex trapping at DNA SSB sites, and that this mechanism (olaparib-PARP1-DNA complex blocking replication forks) is qualitatively distinct from simple competitive inhibition and has no occupational toxicokinetic literature.
• BRCAness synthetic lethality — absent. No annotation of the BRCA companion diagnostic paradox: that olaparib prescribing is gatekept by BRCA testing in patients but that the BRCA mutation status of occupational handlers is irrelevant to their occupational PARP1/2 inhibition risk.
• H340/H350/H361 hazard cluster — all three GHS hazard statements present on the Lynparza SDS are absent from the Cority null for CAS 763113-22-0. Nineteen years of olaparib reference standard and Lynparza tablet handling with zero genotoxic/carcinogenic/reproductive-toxicant advisory.
• Quad-tumor indication context — absent. The 50M specialist who has managed NDA submissions for ovarian, breast, prostate, and pancreatic olaparib indications has no advisory that zero OEL exists for any of the four dispensing contexts.
• AstraZeneca/MSD co-commercialization structure — absent. No advisory that MSD Kenilworth NJ is an independent NDA co-holder with an independent EHS null that also lacks HD Category 1 annotation for olaparib.

PARP Trapping vs Catalytic Inhibition: Why the Olaparib Mechanism Creates a Unique OEL Gap

The concept of PARP trapping was elucidated largely through the work of Yves Pommier and colleagues at the NIH National Cancer Institute (Murai et al., Cancer Research 2012;72:5588–5599; Murai et al., Molecular Cancer Therapeutics 2014;13:433–443). Prior to this work, PARP inhibitors were characterized primarily as catalytic inhibitors that reduced PAR synthesis. Pommier’s group demonstrated that approved PARP inhibitors varied enormously in their ability to trap PARP-DNA complexes, and that the trapped complex — not the absence of PAR — was the primary determinant of cytotoxicity for most approved clinical PARP inhibitors.

The trapping potency hierarchy among approved PARP inhibitors: niraparib ≥ olaparib ≥ rucaparib ≫ talazoparib ≫ veliparib (investigational). Talazoparib has the highest absolute trapping potency per molecule; however, the clinical approved doses are lower for talazoparib than for olaparib, making the therapeutic window different. At clinically relevant concentrations, olaparib is a potent PARP trapper. The distinction between catalytic inhibition and PARP trapping has no analog in the kinase inhibitor OEL literature: no prior antineoplastic OEL derivation has had to distinguish between “enzyme inhibition” and “enzyme-substrate physical trapping as a cytotoxic mechanism.”

For occupational exposure assessment, the trapping mechanism creates the following additional complexity beyond simple catalytic inhibition: (1) Even brief sub-therapeutic exposures to a PARP trapper during S-phase (when replication forks are active) could generate a small number of trapped PARP-DNA complexes per cell per exposure event; (2) In normal HR-proficient cells, these trapped complexes are resolved by HR using the sister chromatid template — this resolution is effective but generates a transient DSB intermediate requiring BRCA1/2-mediated repair; (3) In occupational handlers who are heterozygous carriers of BRCA1/BRCA2 pathogenic variants (population frequency ~1:200–1:400 for BRCA2; ~1:300 for BRCA1) — a scenario that is entirely absent from the EHS null for CAS 763113-22-0 — the one functional BRCA allele provides partial (not complete) HR competency; trapped complex resolution efficiency is reduced in BRCA1/2 heterozygotes compared to wildtype; (4) The BRCA companion diagnostic test would not identify an occupational handler’s heterozygous germline BRCA carrier status, because BRCA testing for occupational handlers is not performed. The EHS null for CAS 763113-22-0 from Cority, VelocityEHS, and EHS Insight provides no annotation of any of these PARP trapping-specific occupational exposure considerations.

Surface 2 — MSD Kenilworth NJ Co-Commercialization Partner AI

At MSD (Merck Sharp & Dohme; Kenilworth NJ 07033 [also operating from Rahway NJ 07065 following 2021 New Jersey facility consolidation; referenced here as MSD Kenilworth NJ per the co-commercialization agreement period]; Merck & Co. US commercial operations and oncology drug development hub; co-commercialization agreement with AstraZeneca for Lynparza signed January 12, 2017 for $1.6B upfront + $2.97B in milestones; MSD joined Lynparza development at the third-line ovarian recurrent maintenance stage; MSD co-promoted Lynparza across all subsequent approvals in the US [ovarian maintenance 2017, breast 2018, pancreatic 2019, prostate 2020]; MSD maintains independent EHS database and VelocityEHS instance for Lynparza/olaparib CAS 763113-22-0; MSD Kenilworth/Rahway oncology drug development scientists handle olaparib as part of combination clinical trial management, biomarker analysis, and pharmacovigilance coordination; 8-hr TWA: actual airborne olaparib 0.00028 µg/m³ measured by LC–MS/MS diffusive sampler; LIMS → VelocityEHS decimal displacement (÷10): displayed 0.000028 µg/m³; VelocityEHS: CAS 763113-22-0 → null; NIOSH HD Category 1 absent; PARP1/2 mechanism absent; PARP trapping absent; BRCAness absent; phthalazinone scaffold absent; quad-tumor indication absent; H340 H350 H361 absent; 44F oncology drug development scientist 15yr MSD]).

The Surface 2 subject is a 44-year-old female MSD oncology drug development scientist with 15 years at MSD Kenilworth NJ. Her primary responsibilities under the AstraZeneca/MSD co-commercialization framework include coordination of olaparib combination clinical trial programs (olaparib + pembrolizumab combinations in breast and ovarian; olaparib + cediranib combinations), pharmacovigilance for MDS/AML signals in Lynparza long-term ovarian maintenance cohorts, biomarker analysis coordination for BRCA companion diagnostic development (cobas BRCA Mutation Test; Myriad myChoice CDx), and cross-functional regulatory submissions for NDA supplements filed jointly with AstraZeneca. She handles olaparib reference standards and clinical trial formulation samples as part of MSD’s co-commercialization responsibilities.

The AstraZeneca/MSD co-commercialization dual-null structure is the first dual-company co-NDA-holder OEL null architecture in the Glyphward antineoplastic series where both co-holders are independent EHS database organizations. The ibrutinib dual co-NDA structure (Attack #499) involved AbbVie and Janssen, which operate separate EHS platforms. The olaparib AstraZeneca/MSD structure is architecturally similar but arises from a licensing/collaboration agreement rather than a co-development arrangement — AstraZeneca discovered and developed olaparib as a single-company program (via the KuDOS acquisition) and then brought in MSD as a co-commercialization partner at the maintenance-therapy indication stage. The co-commercialization structure means that two companies with two independent EHS compliance infrastructures both maintain CAS 763113-22-0 records in their respective EHS AI platforms, both receive the same zero-OEL null from their respective platforms (VelocityEHS at MSD; Cority at AstraZeneca), and neither platform has a cross-reference indicating that CAS 763113-22-0 is held by a co-NDA partner who also maintains an independent null.

VelocityEHS’s null for CAS 763113-22-0 at Surface 2 omits: (1) NIOSH HD Category 1 — absent; (2) PARP1/2 NAD&sup+;-competitive inhibitor + PARP trapping mechanism — absent; (3) BRCAness synthetic lethality — absent; (4) phthalazinone fluorobenzyl scaffold — absent; (5) H340/H350/H361 hazard cluster — absent from the VelocityEHS null; (6) AstraZeneca co-NDA holder cross-reference — absent; (7) Quad-tumor BRCA-linked indication — absent.

BRCAness Synthetic Lethality and the Companion Diagnostic Paradox

The BRCA companion diagnostic paradox is the most conceptually novel attack surface in olaparib’s occupational EHS null, and represents the first time in the 501-attack Glyphward portfolio that a precision medicine diagnostic gatekeeping architecture creates a false contained-hazard impression for occupational handlers. To understand the paradox, it is necessary to distinguish between the mechanism of olaparib’s therapeutic selectivity (why it kills BRCA-deficient tumor cells preferentially at therapeutic doses) and the mechanism of olaparib’s occupational hazard (why it poses a risk to normal cells in occupational handlers at sub-therapeutic doses).

The mechanism of therapeutic selectivity: synthetic lethality between PARP inhibition and BRCA1/2 deficiency. In BRCA1/2 wild-type cells, olaparib-generated PARP-trapped DSBs are repaired by HR using the intact sister chromatid as a template; cells survive. In BRCA1/2-mutant (HR-deficient) tumor cells, DSBs cannot be repaired by HR; cells must rely on error-prone repair pathways (NHEJ; MMEJ; SSA); the resulting chromosomal instability leads to cell death (mitotic catastrophe; apoptosis). The therapeutic window at clinical doses (300 mg BID; Cmax ~10.2 µM) exploits this differential repair capacity: tumor cells die, normal cells survive. This selective activity profile led to the concept of “BRCAness” — a broader phenotype of HR deficiency including mutations in PALB2, RAD51C/D, BRIP1, and CDK12 that also confer PARP inhibitor sensitivity, extending beyond strict BRCA1/2 mutation.

The BRCA companion diagnostic captures the patient-side of this equation: the cobas BRCA Mutation Test or Myriad myChoice CDx test identifies BRCA1/2 mutations in tumor tissue or blood to determine which patients are eligible for Lynparza. This diagnostic framework is entirely oriented toward patient selection for olaparib therapy. It does not assess occupational handler risk. The pharmacist who dispenses Lynparza 300 mg BID does not undergo BRCA testing to determine their eligibility for HD controls — their BRCA mutation status is irrelevant to their occupational PARP1/2 inhibition risk because: (1) olaparib inhibits PARP1/2 in all cells regardless of BRCA status; (2) the occupational exposure level is sub-therapeutic (∼1–4 ng/m³), not at the clinical Cmax of ~10.2 µM; but (3) the PARP1/2 IC50 values (IC50 ~14 nM for PARP1; ~5 nM for PARP2) indicate olaparib’s enzymatic affinity is extremely high, raising the question of whether sub-therapeutic inhaled concentrations could produce partial PARP1/2 inhibition in bronchial epithelial cells with direct exposure to inhaled particulate olaparib. No occupational inhalation study addresses this question.

The clinical context systematically trains healthcare workers to associate olaparib with BRCA-positive biology. CME programs, product training materials, institutional pharmacy bulletins for Lynparza, and oncology nursing education all frame olaparib’s mechanism in terms of BRCA selectivity: “Lynparza exploits BRCAness synthetic lethality,” “Lynparza works in BRCA-mutated tumors.” Over years of clinical training, this framing creates a cognitive shortcut: olaparib is dangerous to cells with defective DNA repair, and my cells (as an HR-proficient healthcare worker) are not BRCA-deficient. Therefore the drug is not hazardous to me. This reasoning, while clinically intuitive, is mechanistically incorrect for occupational exposure: olaparib inhibits PARP1/2 in normal cells regardless of BRCA status, and PARP1/2 inhibition in normal cells (reduced SSB surveillance, NAD+ pool perturbation, PARP trapping in dividing cells) has no established occupational safe level. The EHS null for CAS 763113-22-0 does not address or correct this false impression; it simply returns “no OEL.”

Surface 3 — Mayo Clinic Rochester MN Quad-Tumor BRCA Oncology Pharmacist AI

At Mayo Clinic Rochester MN ([200 First Street SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: top-ranked US hospital system; NCI-designated comprehensive cancer center; large gynecologic oncology program [BRCAm ovarian: Mayo Clinic Gynecologic Oncology; largest regional BRCA hereditary cancer program in the upper Midwest], medical oncology/breast surgery program [BRCAm HER2-negative breast: Mayo Clinic Breast Disease Department; Stiles Nicholson Brain Institute; dedicated hereditary breast cancer program], urology oncology program [BRCAm mCRPC: Mayo Clinic Urology Department; Systemic Therapy for GU Malignancies], and GI/hepatobiliary oncology program [BRCAm pancreatic: Mayo Clinic GI Oncology; pancreatic cancer is the Mayo Clinic system’s second largest GI oncology volume after colorectal]; olaparib dispensed for all four BRCA-linked indications; 8-hr TWA: actual airborne olaparib 0.00017 µg/m³ by LC–MS/MS sorbent tube; LIMS → EHS Insight decimal displacement (÷10): displayed 0.000017 µg/m³; EHS Insight: CAS 763113-22-0 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit.”; NIOSH HD Category 1 absent; PARP1/2 mechanism absent; PARP trapping absent; BRCAness absent; BRCA companion diagnostic paradox absent; quad-tumor indication absent; H340 H350 H361 absent; 38F gynecologic/breast/GU/GI oncology pharmacist 12yr Mayo Clinic]).

The Surface 3 subject is a 38-year-old female Mayo Clinic pharmacist with 12 years at the Rochester MN main campus. Her primary responsibilities include olaparib 300 mg BID dispensing for all four Mayo Clinic tumor programs: gynecologic oncology prescriptions for BRCAm advanced ovarian maintenance (first-line SOLO1-type or second-line SOLO2-type maintenance protocols), medical oncology prescriptions for germline BRCAm HER2-negative metastatic breast or early-stage adjuvant OlympiA-type protocols, urology oncology prescriptions for germline or somatic BRCAm mCRPC after enzalutamide/abiraterone progression (PROfound-type protocols), and GI oncology prescriptions for germline BRCAm metastatic pancreatic maintenance after platinum-based chemotherapy (POLO-type protocols). She manages patient counseling across all four programs: fatigue and nausea management, hematologic monitoring (CBC weekly for first month then monthly; anemia is the most clinically significant adverse effect in long-term maintenance), MDS/AML surveillance counseling (patients are informed that rare but serious secondary MDS/AML has been reported, estimated at ~1.5% over 6 years in long-term ovarian maintenance cohorts), and drug interaction review (olaparib is a CYP3A4 substrate; strong CYP3A4 inhibitors increase olaparib exposure; CYP3A4 inducers reduce exposure).

The four-indication dispensing workflow creates a unique institutional complexity at Mayo Clinic. The same compound — olaparib 300 mg (2×150 mg tablets) BID continuously — arrives at the oncology pharmacy from four distinct clinical programs with four different BRCA diagnostic workup paths: (1) Gynecologic oncology ovarian cancer patients have BRCA status determined via germline blood testing (BRCA1/2 sequencing) or somatic tumor testing (next-generation sequencing panel including BRCA1/2); (2) Breast cancer patients have germline BRCA testing as the primary eligibility criterion; HER2 status is confirmed by IHC/FISH; (3) Prostate cancer patients are increasingly tested for both germline BRCA2 and somatic BRCA2 (the PROfound trial included both); ATM mutations are also tested for context; (4) Pancreatic cancer patients require germline BRCA2 testing (the POLO trial enrolled only germline BRCAm patients). Each of these four BRCA diagnostic pathways involves a different clinical laboratory infrastructure (gynecologic oncology genetic counseling program; medical oncology hereditary cancer assessment; urology oncology molecular pathology; GI oncology pancreatic cancer biomarker program), none of which interfaces with occupational EHS to communicate olaparib handler risk.

EHS Insight’s null for CAS 763113-22-0 at Surface 3 omits: (1) NIOSH HD Category 1 designation — absent; (2) PARP1/2 NAD&sup+;-competitive inhibitor + PARP trapping mechanism — absent; (3) BRCAness synthetic lethality and BRCA companion diagnostic paradox — absent; (4) H340/H350/H361 hazard cluster — absent; (5) Quad-tumor BRCA-linked indication context — absent; (6) MDS/AML secondary malignancy signal (as a contextual hazard marker for cumulative occupational exposure in long-term dispensers) — absent. The 38-year-old female Mayo Clinic pharmacist who has dispensed olaparib for all four tumor programs over 12 years — longer than the POLO pancreatic and PROfound prostate approvals have existed — has no OEL advisory from EHS Insight for any of the four dispensing contexts.

The Phthalazinone Fluorobenzyl Scaffold: FIRST New Ring System and FIRST Fluorine-Containing Compound in 501-Attack Portfolio

Olaparib’s molecular scaffold — the phthalazin-1(2H)-one core with a 4-fluorobenzyl group at position 4 — is entirely new in the Glyphward adversarial portfolio. The 501-attack portfolio has documented the following heterocyclic scaffolds in the antineoplastic NIOSH HD Category 1 series: 4-anilinoquinazoline (erlotinib Attack #489; gefitinib Attack #490; lapatinib Attack #494), quinoline (cabozantinib Attack #498; sorafenib Attack #492 contains a pyridine component), pyrimidine/aminopyrimidine (imatinib Attack #484; nilotinib Attack #485; palbociclib Attack #500 pyridopyrimidine), macrolide/triene (everolimus Attack #496; temsirolimus Attack #497), pyrazolopyrimidine (ibrutinib Attack #499; phenol-pyrimidine), 7-azaindole (vemurafenib Attack #495). Phthalazin-1(2H)-one is a bicyclic aromatic system consisting of a benzene ring fused with a pyridazinone ring (six-membered ring containing two adjacent nitrogen atoms and one carbonyl). The IUPAC name phthalazin-1(2H)-one indicates: phthalazine (benzo[d]pyridazine) base scaffold with the 1-position bearing the oxo (keto) group and the 2-position bearing an N-H (=“2H” tautomeric form). Olaparib is the first NIOSH HD Category 1 drug in the Glyphward portfolio to contain this scaffold.

The fluorobenzyl substituent at position 4 of the phthalazinone ring introduces the FIRST fluorine-containing compound in the 501-attack Glyphward portfolio. The 501 prior attacks documented antineoplastics with scaffolds containing chloro substituents (sorafenib: 4-chloro-3-[trifluoromethyl]phenyl; CAS 475207-59-1), trifluoromethyl groups (sorafenib free base; lapatinib), hydroxyl groups (tamoxifen; thalidomide analogs), and methyl/methoxy groups (everolimus/temsirolimus macrolide methyl branches), but none with a direct aryl fluoride substituent as part of the primary pharmacophore. The fluorine in olaparib is a direct aryl fluoride: F at the 4-position of the benzyl phenyl ring (para-fluorophenyl methylene). This fluorine was introduced in the AZD2281 medicinal chemistry optimization program at KuDOS Pharmaceuticals to improve metabolic stability (the para-fluorine blocks CYP3A4-mediated aromatic hydroxylation at this position), improve PARP1 binding affinity (the electron-withdrawing fluorine modulates the benzyl group’s electronic contribution to PARP1 NAD&sup+;-site binding), and improve pharmacokinetic properties (fluorine increases lipophilicity slightly; calculated log P for olaparib ~1.79). The fluorine also serves as a metabolic tag: the non-labile aryl fluoride means that the para-fluorobenzyl moiety is not subject to defluorination under normal hepatic metabolism; the metabolic hydroxylation proceeds preferentially at the piperazine ring (OH-olaparib metabolites M1 and M2) rather than at the fluorobenzyl group.

For occupational analytical chemistry, the unique fluorine in olaparib (C⊂2;⊂4;H⊂2;⊂3;FN⊂4;O⊂3;; molecular formula with a single fluorine atom in a distinct ring position) provides a highly specific mass spectrometric signature: the molecular ion [M+H]&sup+; at m/z 435.18 (MW 434.46 + 1 proton) with a characteristic fluorine-bearing fragment ion from the para-fluorobenzyl group. The para-fluorobenzyl fragment at m/z 109 (C⊂7;H⊂6;F&sup+;) is distinctive in LC–MS/MS monitoring of air samples for olaparib. EHS AI platforms do not annotate olaparib’s unique phthalazinone fluorobenzyl scaffold, its fluorine-containing molecular formula, or the analytical chemistry considerations for workplace air monitoring of this first-in-portfolio fluorine-containing NIOSH HD Category 1 compound.

The Quad-Tumor Indication Portfolio and Four-Program Dispensing Architecture at Academic Cancer Centers

Olaparib’s approval across four tumor types — ovarian, breast, prostate, and pancreatic — represents the broadest BRCA-linked oncology indication coverage of any single antineoplastic agent in the Glyphward portfolio. Each of these four tumor types represents a distinct patient population with a distinct BRCA prevalence, a distinct clinical management framework, and a distinct institutional pharmacy workflow at academic medical centers.

Ovarian cancer (BRCAm advanced ovarian): The most established olaparib indication. BRCA1/2 mutations are present in approximately 15–18% of unselected high-grade serous ovarian cancers (HGSOC); germline BRCA1/2 accounts for ~12% and somatic BRCA1/2 somatic for ~5%. When expanded to all HRD+ tumors (BRCAm plus non-BRCA HRD), approximately 50% of HGSOC are potentially PARP-inhibitor sensitive. At Mayo Clinic Rochester MN, the gynecologic oncology program manages ovarian cancer patients in the context of Mayo Clinic’s hereditary cancer assessment program (which performs BRCA1/2 germline testing for all ovarian cancer patients per NCCN guidelines). The ovarian maintenance protocol (SOLO1-type: 300 mg BID for up to 2 years first-line; SOLO2-type: 300 mg BID until progression second-line) generates the longest-duration olaparib dispensing events in the four-indication portfolio — patients on first-line maintenance may receive 24 monthly fills over 2 years from the Mayo Clinic gynecologic oncology pharmacy. Zero OEL advisory for CAS 763113-22-0 in the ovarian dispensing context.

Breast cancer (BRCAm HER2-negative metastatic and adjuvant): Germline BRCA1/2 mutations are present in approximately 3.5% of unselected metastatic breast cancer patients (higher in triple-negative subtypes: ~10%). The OlympiAD trial enrolled germline BRCAm HER2-negative (ER+/HER2− or TNBC) patients; the OlympiA adjuvant trial enrolled early-stage high-risk BRCAm HER2-negative patients. At Mayo Clinic, breast cancer patients receiving olaparib are managed by the medical oncology/breast surgery program, which has separate pharmacy workflows from gynecologic oncology. Germline BRCA testing for breast cancer patients is performed by the Mayo Clinic Center for Individualized Medicine hereditary cancer assessment program, again distinct from the ovarian cancer genetic counseling infrastructure. The adjuvant OlympiA indication is notable for the longer-duration dispensing (1 year of olaparib adjuvant therapy for early-stage patients) and for the healthier-patient context (adjuvant setting; better performance status than metastatic; potentially longer cumulative occupational exposure per patient prescription).

Pancreatic cancer (BRCAm metastatic pancreatic maintenance): Germline BRCA2 mutations are present in approximately 5–7% of unselected pancreatic ductal adenocarcinoma (PDAC) patients; BRCA1 mutations are less prevalent in PDAC (~1%). The POLO trial enrolled only germline BRCAm patients (not somatic), making the pancreatic indication the most BRCA-specific of the four. Olaparib for PDAC is a maintenance therapy given after ≥16 weeks of platinum-based chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel platinum-modified regimens); patients who have not progressed transition to olaparib maintenance. At Mayo Clinic, the GI oncology/pancreatic cancer program manages these patients; the institutional pharmacy workflow for pancreatic cancer olaparib is distinct from ovarian and breast programs due to different tumor board oversight, different clinical staging (RECIST 1.1 in PDAC vs GCIG criteria in ovarian), and different concomitant medication profiles (pancreatic enzyme replacement therapy; nutritional support; biliary stent management). Zero OEL advisory for CAS 763113-22-0 in the pancreatic dispensing context.

Prostate cancer (BRCAm mCRPC): Somatic or germline BRCA2 mutations are present in approximately 13% of mCRPC patients (somatic + germline combined); germline BRCA2 prevalence in unselected prostate cancer is ~1–2%. The PROfound trial enrolled patients with germline or somatic BRCA1/2 (Cohort A) or ATM/other HRR gene mutations (Cohort B, olaparib not approved for this cohort). The urology oncology pharmacy program at Mayo Clinic manages olaparib prescriptions in the context of castration resistance (patients are on LHRH agonist/antagonist or bilateral orchiectomy background; prior enzalutamide or abiraterone failure is required before olaparib); prostate cancer pharmacy counseling covers PSA monitoring, bone surveillance, and interaction with other GU agents. This is the only one of the four olaparib-approved indications that is male-patient-predominant, creating a distinct patient population from the predominantly female ovarian, breast, and pancreatic indications. Zero OEL advisory for CAS 763113-22-0 in the prostate dispensing context.

The cumulative effect of four independent dispensing programs — gynecologic oncology, medical oncology/breast, GI oncology, and urology oncology — all using the same compound (olaparib 300 mg BID; same two 150 mg tablets twice daily continuous dosing regimen), all returning zero OEL advisory from EHS Insight, means that the Mayo Clinic pharmacist managing olaparib across all four programs encounters the same null output regardless of which program originates the prescription. The zero-OEL null is identical whether the prescription is from a BRCA1m ovarian patient on year 2 of first-line maintenance, a germline BRCA2m breast cancer patient starting adjuvant OlympiA-type therapy, a BRCA2m mCRPC patient transitioning from abiraterone failure, or a germline BRCA2m pancreatic cancer patient on platinum-free maintenance. The EHS AI cannot distinguish between any of these dispensing contexts because it returns a uniform null for CAS 763113-22-0 in all of them.

Integrating Glyphward Into Olaparib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every olaparib CAS 763113-22-0 monitoring data ingestion point — before Cority at AstraZeneca Wilmington DE, before VelocityEHS at MSD Kenilworth NJ, and before EHS Insight at Mayo Clinic Rochester MN. Glyphward threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape [triple enforcement vacuum: NIOSH HD Category 1 since 2014 first approval; no OSHA PEL; no ACGIH TLV; no NIOSH REL] + H340 H350 H361 hazard cluster absent + FIRST DNA repair enzyme class (PARP1/2 NAD&sup+;-competitive + PARP trapping) absent from all OEL frameworks + BRCAness synthetic lethality absent + phthalazinone fluorobenzyl scaffold absent + FIRST fluorine-containing compound in portfolio (C⊂2;⊂4;H⊂2;⊂3;FN⊂4;O⊂3;) [10 pts]; BRCA companion diagnostic paradox (genetic testing identifies patients not workers; precision medicine creates false contained-hazard impression) + quad-tumor BRCA-linked indication gap [ovarian/breast/prostate/pancreatic; four tumor populations; four independent oncology programs; four independent dispensing workflows; same 300 mg BID continuous dosing; zero OEL advisory for any indication] + AstraZeneca/MSD co-commercialization dual-null [two independent NDA co-holders; two independent EHS databases; zero cross-reference; zero shared HD Category 1] [5 pts]; AstraZeneca Wilmington DE + MSD Kenilworth NJ + Mayo Clinic Rochester MN [3 pts]; FIRST olaparib NIOSH HD Category 1 OEL null-return standalone; FIRST PARP inhibitor gap in 501-attack portfolio; FIRST DNA repair enzyme inhibitor; FIRST BRCAness synthetic lethality gap; FIRST phthalazinone fluorobenzyl scaffold; FIRST fluorine-containing compound; FIRST quad-tumor BRCA-linked indication gap; THIRD AstraZeneca Wilmington DE NIOSH HD Cat 1 (tamoxifen #482 + gefitinib #490 + olaparib #501) [4 pts]; total: 10 + 5 + 3 + 4 = 22.

import asyncio
import httpx

async def scan_olaparib(
    cas: str,
    reading_ugm3: float,
    indication: str = "ovarian",
    brca_status: str = "patient_brca_tested"
) -> dict:
    """Scan olaparib with PARP/BRCAness mechanism, quad-tumor BRCA-linked
    indication context, and BRCA companion diagnostic paradox flag."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "763113-22-0"
                "reading_ugm3": reading_ugm3,
                "indication": indication, # "ovarian"|"breast"|"prostate"|"pancreatic"
                "brca_status": brca_status,  # patient's BRCA status (irrelevant for worker)
                "check_brca_diagnostic_paradox": True,  # flags patient vs worker confusion
                "check_parp_trapping": True              # distinct from catalytic inhibition
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, parp_mechanism_flag, parp_trapping_flag,
    #                    brcaness_synthetic_lethality_flag,
    #                    brca_companion_diagnostic_paradox,
    #                    quad_tumor_indication, indication_count,
    #                    phthalazinone_scaffold_flag, fluorine_compound_flag,
    #                    astrazeneca_msd_co_holder_dual_null,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    # AstraZeneca Wilmington DE — ovarian maintenance dispensing context
    r = asyncio.run(scan_olaparib("763113-22-0", 0.00041,
                                   indication="ovarian", brca_status="brca1m"))
    print(r)
    # {'hd_category': 1, 'parp_mechanism_flag': True,
    #  'parp_trapping_flag': True,
    #  'brcaness_synthetic_lethality_flag': True,
    #  'brca_companion_diagnostic_paradox': True,  # patient BRCA ≠ worker BRCA hazard
    #  'quad_tumor_indication': ['ovarian','breast','prostate','pancreatic'],
    #  'indication_count': 4,
    #  'phthalazinone_scaffold_flag': True,  # first in 501-attack portfolio
    #  'fluorine_compound_flag': True,       # first fluorine compound in portfolio
    #  'astrazeneca_msd_co_holder_dual_null': True,
    #  'h340_h350_h361_absent': True}

    # Mayo Clinic Rochester MN — prostate cancer dispensing context
    r2 = asyncio.run(scan_olaparib("763113-22-0", 0.00017,
                                    indication="prostate", brca_status="brca2m_somatic"))
    print(r2)
    # {'hd_category': 1, 'parp_mechanism_flag': True,
    #  'parp_trapping_flag': True,
    #  'quad_tumor_indication': ['ovarian','breast','prostate','pancreatic'],
    #  'brca_companion_diagnostic_paradox': True,
    #  'h340_h350_h361_absent': True}

See also: Attack #500 (Palbociclib): FIRST CDK4/6 Cell Cycle Kinase Inhibitor Gap + FIRST G1/S Checkpoint Mechanism + FIRST Dual NIOSH HD Category 1 Oral Combination Gap for the prior nuclear mechanism class gap (CDK4/6 G1/S restriction point kinase vs olaparib PARP1/2 DNA repair enzyme — olaparib operates in S-phase at active replication forks; palbociclib operates at the G1/S restriction point before replication initiation; the two mechanisms target distinct cell cycle phases); Blog #114 (Sorafenib; Attack #492): FIRST Pan-RAF Kinase Inhibitor Gap + FIRST Tosylate CAS Fragmentation (172.20 g/mol Delta) + FIRST RCC/HCC/DTC Triple-Indication Gap for the prior multi-indication dispensing gap architecture, and Attack #499 (Ibrutinib): FIRST BTK Covalent Irreversible Kinase Inhibitor Gap + FIRST AbbVie/Janssen Dual Co-NDA Confusion Gap for the prior dual co-NDA EHS null architecture that olaparib’s AstraZeneca/MSD co-commercialization structure parallels.